Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494556 | 0.85 | GABRA1 (0.56) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL16528000 | 0.82 | GABRA1 (0.59) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL6285831 | 0.82 | GABRA1 (0.48) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL30099845 | 0.81 | LMNA (0.52) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL30701932 | 0.81 | LMNA (0.53) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL3823029 | 0.81 | GABRA1 (0.46) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL366229 | 0.81 | GABRA1 (0.52) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL30400912 | 0.80 | TSHR (0.43) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL9556357 | 0.79 | GABRA1 (0.50) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL30411767 | 0.79 | GABRA1 (0.50) | GABRA1GABRB1GABRB2LMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004069779-A1 | METHOD FOR PRODUCING 2,2'-DIHYDROXYBIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | claimed |
| EP-1467958-B1 | PROCESS FOR PREPARING 3,3',5,5',6,6'-HEXAALKYL-2,2'-BIPHENOLS, 3,3',4,4',5,5'-HEXAALKYL-2,2'-BIPHENOLS AND 3,3',4,4',5,5',6,6'-OCTAALKYL-2,2'-BIPHENOLS | INVISTA TECH SARL (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2279993-A1 | Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols, 3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols | INVISTA Technologies S.à.r.l. (CH) | 2011-02-02 | — | — | EP | disclosed |
| EP-1448503-B1 | PROCESS FOR PREPARING 3,3',6,6'-TETRAALKYL-2,2'-BIPHENOLS AND 3,3',6,6'-TETRAALKYL-5,5'-DIHALO-2,2'-BIPHENOLS | INVISTA TECH SARL (US) | 2008-01-30 | — | — | EP | disclosed |
| EP-1214290-B1 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING THEM AND THEIR USE IN HYDROCYANATION REACTIONS | INVISTA TECH SARL (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6812352-B2 | REACTING AN ACYCLIC, ALIPHATIC, MONOETHYLENICALLY UNSATURATED COMPOUND WITH A SOURCE OF HCN IN THE PRESENCE OF A CATALYST PRECURSOR COMPOSITION COMPRISING A LEWIS ACID, A ZERO-VALENT NICKEL, AND A MULTIDENTATE PHOSPHITE LIGAND FOR HYDROCYANATION | INVISTA NORTH AMERICA S.A.R.L. | 2004-11-02 | — | — | US | disclosed |
| US-20040049087-A1 | Process for preparing 3,3',6,6'-tetraalkyl-2,2'-biphenols and 3,3',6,6'-tetraalkyl-5,5'-dihalo-2,2'-biphenols | INVISTA NORTH AMERICA S.A.R.L. (F/K/A ARTEVA NORTH AMERICA S.A.R.L.) | 2004-03-11 | — | — | US | disclosed |
| US-20030100802-A1 | Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols,3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols | SHAPIRO RAFAEL (US) | 2003-05-29 | — | — | US | disclosed |
| US-6555718-B1 | Oxidatively coupling of phenols in presence of Lewis Acid catalysts | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-04-29 | — | — | US | disclosed |
| US-6489517-B1 | CHLORINATING DIALKYLPHENOL, OXIDATIVELY COUPLING PRODUCT IN POLAR APROTIC SOLVENT TO PRODUCE DICHLOROTETRAALKYLBIPHENOL, DECHLORINATING TO PRODUCE TETRAALKYLBIPHENOL, BROMINATING OR IODINATING IF DESIRED | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-12-03 | — | — | US | disclosed |
| EP-1214290-A1 | MULTIDENTATE PHOSPHITE LIGANDS AND CATALYTIC COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001021580-A1 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100802-A1 | Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols,3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols | CYP4B1, UGT1A4, CYP4X1 | GABRA1 1613/4885GABRB1 1560/4885GABRB2 1409/4885 |
| US-20040049087-A1 | Process for preparing 3,3',6,6'-tetraalkyl-2,2'-biphenols and 3,3',6,6'-tetraalkyl-5,5'-dihalo-2,2'-biphenols | CYP2B6, CYP26B1, UGT1A6 | GABRA1 841/4885GABRB1 725/4885GABRB2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.